Menu Search
Equities

Acarix AB

ACARIX:STO

Acarix AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.318
  • Today's Change-0.022 / -6.47%
  • Shares traded5.73m
  • 1 Year change+38.86%
  • Beta1.7490
Data delayed at least 15 minutes, as of Nov 08 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Acarix AB grew revenues 7.20% from 5.82m to 6.24m while net income improved from a loss of 76.99m to a smaller loss of 77.84m.
Gross margin88.27%
Net profit margin-1,133.87%
Operating margin-1,130.43%
Return on assets-101.38%
Return on equity-123.43%
Return on investment-123.43%
More ▼

Cash flow in SEKView more

In 2023, Acarix AB increased its cash reserves by 214.93%, or 23.99m. Cash Flow from Financing totalled 106.23m or 1,702.12% of revenues. In addition the company used 81.37m for operations while cash from investing was breakeven.
Cash flow per share-0.1032
Price/Cash flow per share--
Book value per share0.0697
Tangible book value per share0.0584
More ▼

Balance sheet in SEKView more

Acarix AB has little financial risk as the capital structure does not rely on leverage.
Current ratio5.72
Quick ratio5.21
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.